RE: Volume crossed18 Oct 2023 09:00
Has anybody bothered to read their latest half year report jeez huge losses and cash burn...get the hell out of this while you can...
Financial highlights
-- Loss from operations in H1 2023 of $8.03 million (H1 2022: $8.41 million), a 7% loss decrease year-over-year. This loss largely comprises the costs associated with clinical and regulatory efforts for the US market, public company-related costs, and expanding commercialization reach.
-- Total revenues in H1 2023 were $0.43 million (H1 2022: $0.26 million) a 63% increase during the period, reflecting the additional hospital clinical deployments.
-- Cash, cash equivalents and restricted cash of $4.59 million as at 30 June 2023 (31 December 2022: $13.27 million